LAMATTINA JOHN L sold $1.2M of LGND
LAMATTINA JOHN L sold 4,591 shares of LIGAND PHARMACEUTICALS INC (LGND) at an average of $250.88 ($247.22–$251.62, $1.15M total) across 4 trades on 2026-06-10.
How this was made
The 30-second read
Why it matters
Traders may monitor insider activity as a sentiment input, but Form 4 sales are typically lower-conviction than earnings, guidance, trials, or deal/regulatory updates.
Market read
A director’s ~$1.15M open-market sale is disclosed; likely modest sentiment impact with limited trading edge absent other catalysts.
What to watch
The article provides only the sale details; it does not state whether other insiders/10%-owners increased holdings, nor does it connect the sale to any new company event.
Background
The article is an SEC Form 4 insider transaction disclosure for Ligand Pharmaceuticals (LGND).
Ticker impact
Director John L Lamattina sold $1.15M of LGND shares via open-market transactions on 2026-06-10 (Form 4).
Low likelihood of a sustained price move solely from this Form 4; any impact would be sentiment-driven and likely short-lived.
The filing is a primary-source insider transaction, but it is not tied to a 10b5-1 plan and is a single director’s sale rather than a broader corporate action or fundamental update.
Market effects
Minimal; this is company-specific insider activity with no sector-wide regulatory/clinical/product signal.
None indicated.
None indicated.
Counterpoint
Insider sales can be driven by diversification, taxes, or pre-existing personal liquidity needs; without a 10b5-1 plan, it still may not imply bearish fundamentals.
Key entities
- issuerLIGAND PHARMACEUTICALS INC
Company whose shares were sold by a director via open-market transactions.
- insiderLAMATTINA JOHN L
Director who sold 4,591 shares of LGND for ~$1.15M on 2026-06-10.
